SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for PRAX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 87.46M
March 31, 2026 73.03M
December 31, 2025 59.08M
September 30, 2025 54.68M
June 30, 2025 57.37M
March 31, 2025 54.89M
December 31, 2024 56.30M
September 30, 2024 51.11M
June 30, 2024 44.58M
March 31, 2024 44.12M
December 31, 2023 42.05M
September 30, 2023 45.24M
June 30, 2023 50.37M
March 31, 2023 57.02M
Date Value
December 31, 2022 59.95M
September 30, 2022 61.97M
June 30, 2022 59.75M
March 31, 2022 53.78M
December 31, 2021 47.08M
September 30, 2021 41.37M
June 30, 2021 33.17M
March 31, 2021 24.88M
December 31, 2020 16.99M
September 30, 2020 9.347M
June 30, 2020 7.224M
March 31, 2020 4.704M
December 31, 2019 3.103M
September 30, 2019 1.308M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Insmed, Inc. 893.58M
Perspective Therapeutics, Inc. 29.46M
Vertex Pharmaceuticals, Inc. 2.008B
AbbVie, Inc. 14.67B
TG Therapeutics, Inc. 296.46M